Thyroid cancer among patients with thyroid nodules in Yemen: a three-year retrospective study in a tertiary center and a specialty clinic.
Bethesda
Fine-needle aspiration
Risk of malignancy
Thyroid cancer
Thyroid nodules
Thyroid surgery
Yemen
Journal
Thyroid research
ISSN: 1756-6614
Titre abrégé: Thyroid Res
Pays: England
ID NLM: 101469037
Informations de publication
Date de publication:
2020
2020
Historique:
received:
04
02
2020
accepted:
02
06
2020
entrez:
11
6
2020
pubmed:
11
6
2020
medline:
11
6
2020
Statut:
epublish
Résumé
The prevalence of thyroid cancer is increasing worldwide. No previous data are available on the prevalence of thyroid cancer in Yemen. We performed this study to determine the prevalence of thyroid cancer among patients with thyroid nodules in Yemen. A retrospective chart review was performed for 550 patients with thyroid nodules who underwent fine needle aspiration and/or thyroid surgery at a private endocrine clinic and at an endocrine clinic in a tertiary hospital in Yemen over a 3 -year period from October 2016-2019. The prevalence of thyroid cancer; the sonographic findings, Bethesda classification, age, sex, thyroid stimulating hormone (TSH) levels of the patients; and the nodule size and number were reviewed. A total of 550 charts were reviewed [501 females (91.1%) and 49 males (8.9%)]. The thyroid cancer prevalence among the patients was 13.8% (CI = 10.9-16.7), and the mean age of the patients was 38.5 years (SD = 12.2). The TSH level and the rate of cancer were significantly related (P = 0.01), but no significant difference in the prevalence of thyroid cancer was found between females (13.4%) and males (18.4%) (P = 0.334). When correlating the rate of cancer with the ultrasound guided fine needle aspiration (UG-FNA) result, those with Bethesda system category III and IV, V and VI had malignancy rates of 20.8, 27.2, 52.4 and 69.2%, respectively. Thyroid nodules highly suspicious for malignancy on ultrasound had a 70% cancer diagnosis rate. The most common thyroid cancer was papillary cancer (71%), followed by follicular cancer (23.7%). Among those undergoing surgery, 44.2% had thyroid cancer, and 5.2% had a premalignant diagnosis. Thyroid cancer has a higher prevalence in Yemen than in other middle eastern countries. Our study also reports a higher rate of follicular thyroid cancer than that in other published data, which has to be confirmed by further studies. The malignancy and premalignant diagnosis rate was ~ 50% in our patients who underwent surgery. Many centers in Yemen still do not perform FNA before thyroid surgery. It is important that other centers in the country start emphasizing the need for FNA before surgery. This will decrease the number of unnecessary surgeries and associated complications.
Sections du résumé
BACKGROUND
BACKGROUND
The prevalence of thyroid cancer is increasing worldwide. No previous data are available on the prevalence of thyroid cancer in Yemen. We performed this study to determine the prevalence of thyroid cancer among patients with thyroid nodules in Yemen.
METHODS
METHODS
A retrospective chart review was performed for 550 patients with thyroid nodules who underwent fine needle aspiration and/or thyroid surgery at a private endocrine clinic and at an endocrine clinic in a tertiary hospital in Yemen over a 3 -year period from October 2016-2019. The prevalence of thyroid cancer; the sonographic findings, Bethesda classification, age, sex, thyroid stimulating hormone (TSH) levels of the patients; and the nodule size and number were reviewed.
RESULTS
RESULTS
A total of 550 charts were reviewed [501 females (91.1%) and 49 males (8.9%)]. The thyroid cancer prevalence among the patients was 13.8% (CI = 10.9-16.7), and the mean age of the patients was 38.5 years (SD = 12.2). The TSH level and the rate of cancer were significantly related (P = 0.01), but no significant difference in the prevalence of thyroid cancer was found between females (13.4%) and males (18.4%) (P = 0.334). When correlating the rate of cancer with the ultrasound guided fine needle aspiration (UG-FNA) result, those with Bethesda system category III and IV, V and VI had malignancy rates of 20.8, 27.2, 52.4 and 69.2%, respectively. Thyroid nodules highly suspicious for malignancy on ultrasound had a 70% cancer diagnosis rate. The most common thyroid cancer was papillary cancer (71%), followed by follicular cancer (23.7%). Among those undergoing surgery, 44.2% had thyroid cancer, and 5.2% had a premalignant diagnosis.
CONCLUSION
CONCLUSIONS
Thyroid cancer has a higher prevalence in Yemen than in other middle eastern countries. Our study also reports a higher rate of follicular thyroid cancer than that in other published data, which has to be confirmed by further studies. The malignancy and premalignant diagnosis rate was ~ 50% in our patients who underwent surgery. Many centers in Yemen still do not perform FNA before thyroid surgery. It is important that other centers in the country start emphasizing the need for FNA before surgery. This will decrease the number of unnecessary surgeries and associated complications.
Identifiants
pubmed: 32518593
doi: 10.1186/s13044-020-00082-x
pii: 82
pmc: PMC7275581
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
J Clin Med Res. 2018 Feb;10(2):106-116
pubmed: 29317955
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Cancer Epidemiol. 2013;2013:965212
pubmed: 23737785
Med Sci Monit. 2013 Jan 14;19:49-53
pubmed: 23314590
J Cytol. 2014 Apr;31(2):73-8
pubmed: 25210233
Arq Bras Endocrinol Metabol. 2014 Dec;58(9):933-8
pubmed: 25627049
World J Surg Oncol. 2015 Jun 04;13:193
pubmed: 26041024
Medicine (Baltimore). 2017 Apr;96(16):e6564
pubmed: 28422844
Thyroid. 2013 Aug;23(8):1015-21
pubmed: 23360496
Am J Clin Pathol. 2009 Nov;132(5):658-65
pubmed: 19846805
World J Nucl Med. 2017 Jul-Sep;16(3):202-205
pubmed: 28670178
Thyroid. 2017 May;27(5):641-650
pubmed: 28052718
Cytojournal. 2018 Oct 15;15:24
pubmed: 30410561
Int J Environ Res Public Health. 2019 Apr 09;16(7):
pubmed: 30970543
Eur J Endocrinol. 2008 Nov;159(5):493-505
pubmed: 18728120
J Clin Endocrinol Metab. 2002 Nov;87(11):4924-7
pubmed: 12414851
Saudi Med J. 2004 Jan;25(1):55-9
pubmed: 14758381
J Clin Endocrinol Metab. 2006 Sep;91(9):3411-7
pubmed: 16835280
J Clin Endocrinol Metab. 2016 Jan;101(1):264-74
pubmed: 26529630
J Pathol Transl Med. 2017 Jul;51(4):410-417
pubmed: 28609825
J Clin Endocrinol Metab. 2006 Nov;91(11):4295-301
pubmed: 16868053
World J Clin Oncol. 2017 Apr 10;8(2):151-157
pubmed: 28439496
Epidemiol Health. 2018;40:e2018052
pubmed: 30376709
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Thyroid Res. 2018 Nov 30;11:17
pubmed: 30519286